Drug Combination Details
| General Information of the Combination (ID: C98305) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Trolox Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | HSPA4 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | P388 | CVCL_7222 | Mouse lymphoma | Mus musculus | ||
| In-vivo Model | To establish xenograft model, P388 cells were injected i.p. in DBA/2 mice. | |||||
| Experimental
Result(s) |
Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. Leukemia. 2007 Oct;21(10):2117-27. | |||
